Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Marks and Clerk
Marks and Clerk
Activities:
Finance
Patient Experience
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Taking a multifaceted approach to combatting superbugs
Paul Chapman, Partner at Marks & Clerk LLP, takes a look at research underway for testing a compound on Gram-negative bacteria known for being the most difficult to treat of all infections
Research & Development
UK pharmaceutical patents up 20%
Innovation seen to be key as this sector continues to grow and export its technology to the wider world, reports Marks & Clerk
Finance
UK pharma and biotech patent filings surge, investor confidence sign?
The European Patent Office has reported a surge in pharmaceutical and biotechnology patents – potentially a sign of growing investor confidence in these sectors, according to IP firm Marks & Clerk
Patient Experience
Rare disease patent filings on the rise, finds report, but antibiotics may lose another decade
Research into new antibiotic classes represents less than 5% of antibiotics-related patent filings
Patient Experience
US changes its patent laws
America Invents Act replaces first-to-invent system with first-to-file system
Regulatory
Parliament approves EU unitary patent rules
Patent package includes the unitary patent, language regime and unified patent court
Regulatory
EU moves a step closer to establishing a unitary patent
EU patent protection expected to become less expensive, simpler and more efficient
Subscribe now